[go: up one dir, main page]

TW201642906A - Fixed dose combination for pain relief without edema - Google Patents

Fixed dose combination for pain relief without edema

Info

Publication number
TW201642906A
TW201642906A TW105109708A TW105109708A TW201642906A TW 201642906 A TW201642906 A TW 201642906A TW 105109708 A TW105109708 A TW 105109708A TW 105109708 A TW105109708 A TW 105109708A TW 201642906 A TW201642906 A TW 201642906A
Authority
TW
Taiwan
Prior art keywords
inhibitor
edema
dose combination
pain relief
fixed dose
Prior art date
Application number
TW105109708A
Other languages
Chinese (zh)
Inventor
Vuong Trieu
Original Assignee
Autotelic Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/011148 external-priority patent/WO2016114761A1/en
Application filed by Autotelic Llc filed Critical Autotelic Llc
Publication of TW201642906A publication Critical patent/TW201642906A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (iCOX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor. Provided is a composition for treating pain without inducing edema comprising a COX-2 inhibitor and a diuretic, wherein the composition is administered in a fixed-dose combination.
TW105109708A 2014-06-08 2016-03-28 Fixed dose combination for pain relief without edema TW201642906A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462009300P 2014-06-08 2014-06-08
US201462023962P 2014-07-14 2014-07-14
PCT/US2015/011148 WO2016114761A1 (en) 2015-01-13 2015-01-13 Method for individualized drug therapy
PCT/US2015/034706 WO2015191460A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema

Publications (1)

Publication Number Publication Date
TW201642906A true TW201642906A (en) 2016-12-16

Family

ID=54834151

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105109708A TW201642906A (en) 2014-06-08 2016-03-28 Fixed dose combination for pain relief without edema
TW105109706A TW201642854A (en) 2014-06-08 2016-03-28 Fixed dose combination for pain relief without edema

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105109706A TW201642854A (en) 2014-06-08 2016-03-28 Fixed dose combination for pain relief without edema

Country Status (8)

Country Link
EP (2) EP3151823A4 (en)
JP (2) JP2017517575A (en)
KR (2) KR20160091348A (en)
CN (2) CN106572984A (en)
AU (2) AU2015274908A1 (en)
CA (2) CA2956899A1 (en)
TW (2) TW201642906A (en)
WO (2) WO2015191473A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115057A1 (en) * 2015-01-13 2016-07-21 Autotelic Llc Fixed dose combination for pain relief without edema
US20200306211A1 (en) * 2015-11-30 2020-10-01 Pharnext Method for adapting doses of combination therapies
CN115023223A (en) 2019-12-04 2022-09-06 雷斯乔制药有限责任公司 Methods and compositions for treating oral diuretic refractory edema

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005799A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
WO2006058073A2 (en) * 2004-11-23 2006-06-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising a selective cox-2 inhibitor and a diuretic
US20090215852A1 (en) * 2005-03-21 2009-08-27 Chroma Group, Inc. Compositions and methods for ameliorating cachexia
EP2014284A1 (en) * 2007-06-15 2009-01-14 Novartis AG Pharmaceutical compositions and uses
AU2009260632A1 (en) * 2008-05-28 2009-12-23 Kitov Pharmaceuticals Ltd. Pharmaceutical formulations and methods of use which combine non-steroidal anti-inflammatory compounds with anti-hypertensive compounds
JP6184943B2 (en) * 2011-05-30 2017-08-23 オートテリック エルエルシー Methods and compositions for therapeutic drug monitoring and dose administration with point-of-care pharmacokinetic profiles

Also Published As

Publication number Publication date
EP3151823A1 (en) 2017-04-12
CA2956897A1 (en) 2015-12-17
EP3151822A4 (en) 2017-11-22
KR20160091348A (en) 2016-08-02
AU2015274895A1 (en) 2017-02-02
JP2017517529A (en) 2017-06-29
CA2956899A1 (en) 2015-12-17
AU2015274908A1 (en) 2017-01-19
WO2015191460A1 (en) 2015-12-17
JP2017517575A (en) 2017-06-29
KR20160091349A (en) 2016-08-02
WO2015191473A1 (en) 2015-12-17
EP3151822A1 (en) 2017-04-12
CN106572985A (en) 2017-04-19
TW201642854A (en) 2016-12-16
WO2015191473A9 (en) 2016-03-24
EP3151823A4 (en) 2017-11-22
CN106572984A (en) 2017-04-19

Similar Documents

Publication Publication Date Title
MX2024010140A (en) NEW METHODS.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MY188139A (en) Sodium channel modulators for the treatment of pain
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
WO2016090024A3 (en) Combination therapy for treatment of cancer
BR112017009986A2 (en) methods for treating individuals with prader-willi syndrome or smith-magenis syndrome
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
WO2014153385A3 (en) Methods of treating metabolic disorders
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201501164A1 (en) SOLID PHARMACEUTICAL MEDICINE FORM
MX2019005309A (en) Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use.
TW201642906A (en) Fixed dose combination for pain relief without edema
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
PH12015501538A1 (en) Topical ocular analgesic agents
MX2014005152A (en) Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient.
MX2016010399A (en) Topical formulations of heparin.
UA104582U (en) A method for treating uncomplicated varicose veins
AR106220A1 (en) SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS
UA95104U (en) METHOD OF THERAPY OF PATIENTS WITH NON-HOSPITAL PNEUMONIA WITH COMPLETE CHF
EA201692163A1 (en) MEDICINE FOR THE TREATMENT OF PATIENTS WITH TINNITUS
UA95834U (en) Method for treating acute ischemic stroke